HealthQuill semaglutide
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Health Medical Pharma

Novo Nordisk’s Ozempic receives EMA’s nod for chronic kidney disease treatment

HQ Team December 13, 2024: Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

Read More
Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without worsening the condition.
Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces live scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.

Read More
Denmark’s Novo Nordisk declared its late-stage experimental once-weekly diabetes drug IcoSema achieved its primary endpoint of proving “non-inferiority” in lowering blood sugar levels.
Drugs Health Medical

Breakthrough treatment may end insulin use in type 2 diabetic patients

HQ Team October 15, 2024: A recent study presented at the United European Gastroenterology Week congress in Vienna unveiled a procedure that could.

Read More
Semaglutide based weightloss drugs tied to increased suicide risk in a new study
Drugs Health Pharma

New study stirs up semglutide and suicide link debate

HQ Team August 22, 2024: A new study based on data from the World Health Organization’s records on adverse drug reactions found that.

Read More
cigarette smoke
Drugs Health Pharma

Diabetes and weight loss drug can help quit smoking, finds new study

HQ Team July 31, 2024: A new research published in the Annals of Internal Medicine reveals that semaglutide is effective in helping people quit.

Read More
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic adults with obesity, according to a statement from the EU regulator.
Drugs Health Pharma

Wegovy gets EU regulator backing on lowering heart risks in obese people

The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.

Read More
The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering from heart problems or stroke.
Drugs Health Pharma

Novo Nordisk’s Wegovy gets UK regulator nod to treat heart risks

The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Health Pharma

7-fold increase in use of GLP-1 weight loss drugs among teens, young adults

Research finds a sharp increase in use of weightloss drugs such as Ozempic and Wegovy among teens and young adults

Read More
Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company announced.
Drugs Health Pharma

Novo Nordisk unveils new drug to fight obesity, says 13% effective

HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.

Read More
Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24% of people involved in trials, the company announced.
Drugs Health Pharma

Novo Nordisk says Ozempic reduces kidney disease progression 

HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.

Read More